Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom

Davinia Pla; Yania Rodríguez; Dabor Resiere; Hossein Mehdaoui; José María Gutiérrez; Juan J Calvete

doi:10.1016/j.toxcx.2018.100004

Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom

Toxicon X. 2018 Dec 29:1:100004. doi: 10.1016/j.toxcx.2018.100004. eCollection 2019 Jan.

Authors

Davinia Pla¹, Yania Rodríguez¹, Dabor Resiere², Hossein Mehdaoui², José María Gutiérrez³, Juan J Calvete¹

Affiliations

¹ Laboratorio de Venómica Evolutiva y Traslacional, Instituto de Biomedicina de Valencia, CSIC, Jaime Roig 11, 46010 Valencia, Spain.
² Service des Urgences et de Reanimation Polyvalente, Centre Hospitalier Universitaire, Fort-de-France, Martinique, France.
³ Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica.

Abstract

Bothrops lanceolatus inflicts severe envenomings in the Lesser Caribbean island of Martinique. Bothrofav®, a monospecific antivenom against B. lanceolatus venom, has proven highly effective at the preclinical and clinical levels. Here, we report a detailed third-generation antivenomics quantitative analysis of Bothrofav®. With the exception of poorly-immunogenic peptides, Bothrofav® immunocaptured all the major protein components. These results, along with previous preclinical and clinical observations, underscore the high neutralizing efficacy of the antivenom against B. lanceolatus venom.

Keywords: Antivenom; Bothrofav®; Bothrops lanceolatus; Martinique; Snake venom; Third-generation antivenomics.